DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Pivot X, Romieu G, Debled M. et al.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol 2013;
14: 741-748
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.